SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,809,410,222 |
| Positions | 32 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $198,065,407 | 5,322,908 |
| SYNDAX PHARMACEUTICALS INC | SNDX | COM | $175,993,964 | 8,050,959 |
| VAXCYTE INC | PCVX | COM | $169,875,334 | 2,922,335 |
| COGENT BIOSCIENCES INC | COGT | COM | $141,916,654 | 3,667,097 |
| VERA THERAPEUTICS INC | VERA | CL A | $124,012,432 | 2,890,059 |
| VIRIDIAN THERAPEUTICS INC | VRDN | COM | $118,557,720 | 6,453,877 |
| TRAVERE THERAPEUTICS INC | TVTX | COM | $113,620,000 | 2,000,000 |
| BEAM THERAPEUTICS INC | BEAM | COM | $97,495,981 | 2,840,792 |
| UROGEN PHARMA LTD | URGN | COM | $89,578,818 | 2,434,207 |
| LEGEND BIOTECH CORP | LEGN | SPONSORED ADS | $86,674,800 | 3,001,205 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.